Applied Therapeutics announces that its Board of Directors is exploring strategic alternatives to maximize shareholder value, including mergers, acquisitions, and partnerships.
The Company is reducing its workforce by 46% as part of cost-containment measures while emphasizing its commitment to bringing govorestat to patients with rare diseases.
Regulatory updates include discussions with the FDA for govorestat's potential Phase 3 trial designs in Charcot-Marie-Tooth Sorbitol Dehydrogenase (CMT-SORD) and Classic Galactosemia.
Strategic Alternatives Exploration
Board of Directors evaluating various opportunities to maximize shareholder value through mergers, acquisitions, partnerships, and other strategic transactions.
Workforce Reduction
Company reducing workforce by 46% alongside cost-containment measures to preserve cash runway and pursue optimal path forward.
Regulatory Updates
Engagement with FDA for potential Phase 3 trial designs of govorestat for CMT-SORD and Classic Galactosemia treatment.
- The strategic review process aims to enhance shareholder value and secure the Company's future direction through potential transactions or partnerships.
- The workforce reduction and cost-containment measures reflect a proactive approach to maintaining financial stability while advancing drug development programs.
Applied Therapeutics is strategically positioning itself for growth and value creation while maintaining focus on drug development for rare diseases. The regulatory updates underscore the Company's commitment to advancing treatments for conditions like CMT-SORD and Classic Galactosemia.